DDInter596 DDInter574
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021.
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Doxorubicin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Doxorubicin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Doxorubicin {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Doxorubicin {u} (Compound) causes {v} (Side Effect) Dermatitis contact
Dermatitis contact {u} (Side Effect) is caused by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Diroximel fumarate
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may lead to a major life threatening interaction when taken with {v} Trastuzumab
Trastuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Doxorubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Bexarotene (Compound) and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Doxorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bexarotene (Compound) and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Doxorubicin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Bexarotene (Compound) and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Doxorubicin (Compound) causes Dermatitis contact (Side Effect) and Dermatitis contact (Side Effect) is caused by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may cause a minor interaction that can limit clinical effects when taken with Melphalan and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may lead to a major life threatening interaction when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate